Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Simone Mester, Mitchell Evers, Saskia Meyer, Jeannette Nilsen, Victor Greiff, Inger Sandlie, Jeanette Leusen & Jan Terje Andersen. (2021) Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo. mAbs 13:1.
Read now
Read now
Chen Li, Shijie Dai, Aijie Cao, Zhifang Zhou & Zhimeng Wu. (2019) Design and synthesis of rhamnose-modified exenatide conjugate by sortase A-mediated ligation. Journal of Carbohydrate Chemistry 38:3, pages 167-178.
Read now
Read now
Articles from other publishers (13)
Mihaela-Simona Popoviciu, Lorena Păduraru, Galal Yahya, Kamel Metwally & Simona Cavalu. (2023) Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. International Journal of Molecular Sciences 24:13, pages 10449.
Crossref
Crossref
Yaochen Xie, Qian Zhou, Qiaojun He, Xiaoyi Wang & Jincheng Wang. (2023) Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition. Acta Pharmaceutica Sinica B 13:6, pages 2383-2402.
Crossref
Crossref
Poonam Yadav, Amit Khurana, Jasvinder Singh Bhatti, Ralf Weiskirchen & Umashanker Navik. (2022) Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective. Pharmacological Research 184, pages 106426.
Crossref
Crossref
Cláudia Azevedo, Soraia Pinto, Sopisa Benjakul, Jeannette Nilsen, Hélder A. Santos, Giovanni Traverso, Jan Terje Andersen & Bruno Sarmento. (2021) Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery. Advanced Drug Delivery Reviews 175, pages 113778.
Crossref
Crossref
Sanjay Kalra, Saptarshi Bhattacharya & Nitin Kapoor. (2021) Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs). Diabetes Therapy 12:8, pages 2133-2147.
Crossref
Crossref
Amélia Galdino Ribeiro, Josival Emanuel Ferreira Alves, José Cleberson Santos Soares, Keriolaine Lima dos Santos, Íris Trindade Tenório Jacob, Cindy Juliane da Silva Ferreira, Jéssica Celerino dos Santos, Rafael David Souto de Azevedo, Sinara Mônica Vitalino de Almeida & Maria do Carmo Alves de Lima. (2021) Albumin roles in developing anticancer compounds. Medicinal Chemistry Research 30:8, pages 1469-1495.
Crossref
Crossref
Alina Kondrashina, Shauna Heffernan, Nora O’Brien & Linda Giblin. 2021. Biologically Active Peptides. Biologically Active Peptides
629
664
.
Malin Bern, Jeannette Nilsen, Mattia Ferrarese, Kine M. K. Sand, Torleif T. GjølbergHeidrun E. Lode, Robert J. DavidsonRodney M. CamireEspen S. BækkevoldStian Foss, Algirdas Grevys, Bjørn Dalhus, John WilsonLene S. Høydahl, Gregory J. Christianson, Derry C. Roopenian, Tilman SchlothauerTerje E. Michaelsen, Morten C. Moe, Silvia Lombardi, Mirko Pinotti, Inger SandlieAlessio Branchini & Jan Terje Andersen. (2020) An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics. Science Translational Medicine 12:565.
Crossref
Crossref
Anthony P. Davenport, Conor C. G. Scully, Chris de Graaf, Alastair J. H. Brown & Janet J. Maguire. (2020) Advances in therapeutic peptides targeting G protein-coupled receptors. Nature Reviews Drug Discovery 19:6, pages 389-413.
Crossref
Crossref
Jeannette Nilsen, Esben Trabjerg, Algirdas Grevys, Claudia Azevedo, Stephen O. Brennan, Maria Stensland, John Wilson, Kine Marita Knudsen Sand, Malin Bern, Bjørn Dalhus, Derry C. Roopenian, Inger Sandlie, Kasper Dyrberg Rand & Jan Terje Andersen. (2020) An intact C-terminal end of albumin is required for its long half-life in humans. Communications Biology 3:1.
Crossref
Crossref
Angelo Maria Patti, Ali A Rizvi, Rosaria Vincenza Giglio, Anca Pantea Stoian, Daniela Ligi & Ferdinando Mannello. (2020) Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. Journal of Clinical Medicine 9:4, pages 912.
Crossref
Crossref
Manfredi Rizzo, Dragana Nikolic, Angelo Maria Patti, Carlo Mannina, Giuseppe Montalto, Brooke S. McAdams, Ali A. Rizvi & Francesco Cosentino. (2018) GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1864:9, pages 2814-2821.
Crossref
Crossref
André J. Scheen. (2018) GLP-1 receptor agonists and cardiovascular protection: A class effect or not?. Diabetes & Metabolism 44:3, pages 193-196.
Crossref
Crossref